Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors

Jaroslav A. Hubacek a,*, Ladislav Dusek b,c, Ondrej Majek b,c, Vaclav Adamek d, Tereza Cervinkova e, Dana Dlouha a, Vera Adamkova d,e

a Experimental Medicine Center, Institute for Clinical and Experimental Medicine, Videnska 1958/9, Prague, Czech Republic
b Institute of Health Information and Statistics of the Czech Republic, Palackeho namesti 4, Prague, Czech Republic
c Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Kamenice753/5, Brno, Czech Republic
d Czech Technical University, Faculty of Biomedical Engineering, Sítna 3105, Kladno, Czech Republic
e Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Videnska 1958/9, Prague, Czech Republic

* Corresponding author at: IKEM-EMC, Videnska 1958/9, 14021 Prague 4, Czech Republic.
E-mail address: jahb@ikem.cz (J.A. Hubacek).

https://doi.org/10.1016/j.cca.2021.04.024
Received 27 April 2021; Received in revised form 29 April 2021; Accepted 29 April 2021
Available online 3 May 2021
0009-8981/© 2021 Elsevier B.V. All rights reserved.

1. Introduction

Infection by SARS-CoV-2 represents a new emerging healthy situation around the globe. The infection emerged in China probably at the end of 2019 and rapidly spread to all continents. The novel virus named SARS coronavirus 2 (SARS-CoV-2) is associated with the pneumonia-associated disease known as COVID-19 (COronaVIrus Disease – 2019). In contrast to other coronavirus-associated diseases (SARS, MERS), COVID-19 is a far milder upper respiratory tract illness but has superior transmission capability [2,3].

Very quickly, it has been recognized that there are significant geographical and interethnic variations in COVID-19 prevalence [2,4,5] and COVID-19-associated mortality. The variability in the host immune system [6,7] caused by genetic background might partly explain the described prevalence differences.

Among the candidates with the potential to affect SARS-CoV-2 infection and COVID-19 symptoms and severity, the ACE gene is often mentioned and has been extensively examined in several studies (for example, see [8–10]).

ACE (angiotensin I-converting enzyme, alias kininase II; OMIM acc. No. 106180) is an important part of the renin-angiotensin–aldosterone system (RAAS). ACE2, another member of the RAAS family, is recognized as a gateway for SARS-CoV-2 particle entry into cells, serving as their receptor [11]. However, variants within ACE2 were not associated with the prevalence or severity of SARS during the 2003/2004 outbreak [12].

Within the Alu sequence of intron 16 of the ACE gene, there is a functional polymorphism, represented by an insertion/deletion (I/D) of 287 bp (rs4646994). The D allele is significantly associated with increased activity and concentration of the enzyme [13], but associations with blood pressure or with increased cardiovascular risk were found in some but not in all studies (summarized by [14–16]).

Insertion/deletion ACE polymorphisms exhibit some significant geographical and ethnic variability, where the frequency of the I allele
is increased in Asian and African populations in comparison to that in Caucasians.

As a detailed analysis of the COVID-19 course and I/D ACE polymorphism has not yet been performed, our study focused on analysis of the I/D polymorphism within the ACE gene in symptomatic and asymptomatic SARS-CoV-2-positive patients from the first COVID-19 wave in the Czech Republic.

2. Material and methods

2.1. Subjects

The ACE I/D polymorphism was genotyped in 410 COVID-19 subjects (Table 1) who tested positive for the presence of SARS-CoV-2 infection (and completely recovered at the time of sample collection – July 2020) during the first wave (app. March 2020 – June 2020) of the disease in the Czech Republic [17]. Of them, 164 were asymptomatic, and 246 were symptomatic (without hospitalization).

As controls, 2,559 adults were used (post-MONICA study [18,19]; random 1% population sample from 9 districts, stratified by age and sex). Their ACE genotypes were known from a previous study [20]. Written informed consent was provided by all subjects involved in the study. The study protocol was approved by the institutional ethics committee.

2.2. DNA analysis

DNA was isolated from EDTA-treated blood [21]. The ACE I/D polymorphism was genotyped as described in detail by Rigat et al. [22]. PCR products of ~490 bp and ~200 bp characterise the I and D alleles, respectively. All D/D subjects were regenotyped with ACE I-specific oligonucleotides according to Ueda et al. [23] to avoid the mis-genotyping of some I/D heterozygotes as D/D homozygotes. Based on confirmatory genotyping, 51 (3.8%) controls and 4 (0.9%) patients primarily genotyped as D/D were reclassified as I/D. PCR was performed on an MJ Research DYAD Disciplex PCR device (MJ Research, MA, US), and all chemicals were produced by Fermentas International Inc. (Burlington, Ontario, Canada).

2.3. Statistical analysis

Statistical analysis has been performed using the www.socscistatistics.com tools (accessed 12/2020).

3. Results

The achieved call rate was 99.5% for COVID-19 patients and 98.2% for controls. In both the patient and control groups, the genotype frequencies were in agreement with Hardy-Weinberg equilibrium.

We observed significant differences in genotype frequencies of the ACE I/D polymorphisms between the patients and controls (for additional details, see Table 2).

The frequency of ACE I/I homozygotes was significantly increased in the entire group of COVID-19 patients compared with that in the controls (26.2% vs. 21.2%; P = 0.02; OR [95% CI] = 1.55 [1.17–2.05] for I/I vs. + D comparison).

| Table 1 | General characteristics of controls and COVID-19-positive subjects. |
|---------|-----------------------------|
|         | Controls | Patients |
| N       | 2,579     | 410      |
| Age (years) | 48 ± 11 |
| % female | 53.4     | 54.7     |
| Diabetes (%) | 8.2 |
| Hypertension (%) | 22.3 |

Importantly, however, the difference was driven by the symptomatic subjects only (29.0% vs. 21.2% of I/I homozygotes; P = 0.005; OR [95% CI] = 1.51 [1.13–2.02] for I/I vs. + D comparison; P = 0.0025; OR [95% CI] = 1.78 [1.22–2.60] for D/D vs. I/I comparison).

The genotype distribution of the ACE genotypes was almost identical in population controls and asymptomatic SARS-CoV-2-positive patients (P = 0.79; OR [95% CI] 1.05 [0.72–1.54]; for additional details, see Table 2).

4. Discussion

In our study, we detected a significant effect of the ACE insertion/deletion polymorphism on the risk of symptomatic SARS-CoV-2 infection/COVID-19.

The I/D polymorphism within the ACE gene is among the heavily discussed inherited variants with the potential to influence the COVID-19 outcome [8,10,24,25], but especially as papers mostly have no direct patient data the conclusions are not uniform but rather contradictory. Some papers are suggesting the D allele and others suggesting the I allele as deleterious.

Mostly, the ecological studies used mortality data from different dates, which could lead to misreporting as the pandemic has different course due to time in different countries. Further, there are important regional differences in spread of pandemic within the countries and finally, for identical countries, different I/D ratios and different models (dominant or recessive) were used for calculation.

For example, our results are in agreement with the results described by Delanghe et al. [8,26]. They compared the numbers of fatalities, related both per million inhabitants and per number of total cases, within the first COVID-19 wave in data from dozens of European countries and recognized the I/I genotype as deleterious.

The functional link between ACE I/D polymorphism and infectivity and pathogenicity of the SARS-Cov-2 virus has been recently proved by Jacobs et al. [27]. In I/I homozygotes, increased ACE2 protein levels in lung epithelium has been detected – this can facilitate the virus entry into the host organism as ACE2 is used by the virus as gateway for cell entry.

Studies performed on Asian populations [24,28,29], reported opposite results and suggested a D/D genotype as a predictive marker of COVID-19 severity. These discrepancies could be caused by the fact, that there could be ethnicity specific allelic effect similar to the effect of response on ACE inhibitor treatment (see below, [30]. Different conclusions reached are indirectly confirmed by the fact that some nonwhite ethnicities with increased COVID-19 mortality exhibit an increased population frequency of the I allele.

However, the studies are very difficult to compare. The major difference between our and these studies is in the protocol performed. Furthermore, these studies have generally extrapolated the available data about the ACE I/D genotype frequencies and publicly available data about the prevalence of the disease. In contrast to the abovementioned studies, we have direct access to the patient DNA, COVID – 19 status and we have the possibility to compare the ACE genotype frequencies directly with the large and population based sample. The abovementioned studies focused on mortality cases, which is in contrast with our study, which is focused on survivors and compares symptomatic and asymptomatic subjects. In contrast, we focused on concrete subjects, individuals who tested positive for suffering from SARS-CoV-2 infection, and linked the exact genotype with disease symptoms. Despite these differences, we have obtained similar results.

Importantly, a large cohort study performed in England detected that ACE inhibitor treatment was associated with a significantly (with a HR of approximately 0.7) reduced risk of COVID-19 [30], even after multiple adjustments. Furthermore, it cannot be excluded that the ACE I/D polymorphism could play different roles in different stages of infection and disease as well as in different ethnicities, as ACE inhibitors seem to be protective against COVID-19 in white UK subjects but in contrast
even deleterious in nonwhite UK subjects. It would be of interest to study whether there is some interaction between ACE genotypes and ACE inhibitors in susceptibility to symptomatic COVID-19.

Among other factors, male sex, obesity, diabetes and nonwhite ethnicity are reported to be associated with an increased risk of COVID-19 [4]. Within the control group, we did not detect any association between the ACE I/D polymorphism and blood pressure, body mass index or the presence of diabetes mellitus, suggesting a context-independent association with disease.

The possibility of predicting symptomatic COVID-19 using a simple, quick and inexpensive test based on individual subject DNA polymorphisms could be very important in general testing to distinguish between subjects with high and low risk of disease and, importantly, for the estimation of the severity of the disease. It is certain that the analysis of one polymorphism will not be sufficient, and the examination of a wide list of polymorphisms will be necessary. Creation of the genetic risk score reflecting the host ability to affect the individual’s sensitivity to COVID-19 could be important.

The COVID situation has evoked a wave of interest focused on potential host genetic predisposition to the disease. The list of suggested polymorphisms [6] with potential to affect SARS-CoV-2 susceptibility is long (including, for example, genes for vitamin D receptor, MBL and CLEC4M), but so far, undoubtedly confirmed and widely replicated genetic determinants of SARS-CoV-2 infection and COVID-19 severity remain unknown.

Genetic susceptibility to COVID-19 was also examined using the genome-wide association approach [31]. This study detected a few useful signals within the ABO blood-group system, suggesting a benefit in blood group 0 and increased risk associated with blood group A. The second strongest signal was localized at the 3p21.31 locus, where promising candidates, such as genes for two chemokine receptors, CCR9 and CXCR6, or the gene for SLC6A20, which interacts with ACE2, are localized.

Nonetheless, the differences in the prevalence of disease suggest possible nonuniversality of the involved genes/variants, as suggested by our results, where the ACE I/I genotype is associated with the symptomatic course of the disease.

5. Conclusion

The results of our study suggest that ACE I/I homozygotes may be at an increased risk of symptomatic COVID-19, at least in East European Caucasians.

Funding

The study was supported by Ministry of Health, Czech Republic - conceptual development of research organization (“Institute for Clinical and Experimental Medicine – IKEM, IN 00023001”).
J.A. Hubacek et al.

Clinica Chimica Acta 519 (2021) 206–209

2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven pro tease inhibitor, Cell 20 (2020), 271–80.e8, https://doi.org/10.1016/j.cell.2020.02.002.

[12] R.W. Chiu, N.L. Tang, D.S. Hui, G.T. Chung, S.S. Chim, K.C. Chan, Y.M. Sung, L. Y. Chan, Y.K. Tong, W.S. Lee, P.K. Chan, Y.M. Lo, ACE2 gene polymorphisms do not affect outcome of severe acute respiratory syndrome, Clin. Chem. 50 (2004) 1683–1686, https://doi.org/10.1373/clinchem.2004.035416.

[13] F. Cambien, F. Alhenc-Gelas, B. Hereth, J.L. Andre, R. Rakotavo, M.F. Gonzales, J. Allegrini, C. Bloch, Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy Study, Am. J. Hum. Genet. 43 (1988) 774–780.

[14] J.A. Hubacek, R. Poledne. [Insertion/deletion polymorphism in the gene for angiotensin-converting enzyme and cardiovascular disease]. Cor Vasa. 41 (1999) 149–54. Article in Czech.

[15] B. Agerholm-Larsen, B.G. Nordestgaard, A. Tybjaerg-Hansen, ACE gene polymorphism and cardiovascular disease: meta-analyses of small and large studies in whites, Arterioscler. Thromb. Vasc. Biol. 20 (2000) 484–492, https://doi.org/10.1161/01.atv.20.2.484.

[16] B. Mayer, H. Schunkert, ACE-Gen-Polymorphismus und kardiovaskulare Erkrankungen [ACE gene polymorphism and cardiovascular diseases]. Herz. 25 (2000) 1-6. Article in German. https://doi.org/10.1007/BF03044118.

[17] J.A. Hubacek, L. Dusek, O. Majek, V. Stanek, M. Gebauerová, J. Hubacek, A. Kruger, M. Penicka, H. Hrabáková, J. Adamek, V. Adamkova, V. Longitudinal study in the Czech population: a growing burden of cardiovascular disease [ACE gene polymorphism and cardiovascular diseases]. Czech MONICA and Czech post-MONICA, Atherosclerosis 211 (2010) 681, https://doi.org/10.1016/j.atherosclerosis.2010.04.007.

[18] S. Verma, M. Abbas, S. Verma, F.H. Khan, S.T. Raza, Z. Siddiqi, I. Ahmad, F. Mahdi, R. Poledne, P. Stachura, J. Pitha, A FTO variant and risk of acute coronary syndrome, Clin. Chim. Acta 411 (2010) 1069–1072, https://doi.org/10.1016/j.cca.2010.03.037.

[19] J.A. Hubacek, J. Pitha, I. Podrapska, J. Sochman, V. Adamkova, V. Longitudinal study in the Czech population: a growing burden of cardiovascular disease [ACE gene polymorphism and cardiovascular diseases]. Czech MONICA and Czech post-MONICA, Atherosclerosis 211 (2010) 681, https://doi.org/10.1016/j.atherosclerosis.2010.04.007.

[20] J.A. Hubacek, D. Dykes, H.P. Polesky, A simple salting out procedure for DNA extraction from human nucleated cells, Nucleic Acid Res. 16 (1988) 1215, https://doi.org/10.1093/nar/16.3.1215.

[21] S.A. Miller, D.D. Dykes, H.P. Polesky, PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase I), Nucleic Acids Res. 20 (1992) 1433, https://doi.org/10.1093/nar/20.6.1433-a.

[22] S. Ueda, R.P. Heerey, K.R. Lees, H.L. Elliott, J.M. Connell, Misting the human angiotensin-converting enzyme gene polymorphism: frequency, causes and possible methods to avoid errors in typing, J. Mol. Endocrinol. 17 (1996) 27–30, https://doi.org/10.1677/jme.0.0170027.

[23] N. Yamamoto, Y. Ariumi, N. Nishida, R. Yamamoto, G. Bauer, T. Gojobori, K. Shimotohno, M. Miura, SARS-CoV-2 infections and COVID-19 mortalities strongly correlate with ACE1 I/D genotype, Gene 758 (2020), 144944, https://doi.org/10.1016/j.gene.2020.144944.

[24] M. Saadat, No significant correlation between ACE Ins/Del genetic polymorphism and COVID-19 infection, Clin. Chem. Lab. Med. 58 (2020) 1127–1128, https://doi.org/10.1515/cclm-2020-0577.

[25] J.R. Delanghe, M.M. Speeckaert, M.L. De Buyzere, The host’s angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections, Clin. Chim. Acta 505 (2020) 192–193, https://doi.org/10.1016/j.cca.2020.03.031.

[26] M. Jacobs, L. Lahousse, H.P. Van Eckhoutte, S.R.A. Wijnant, J.R. Delanghe, G. Brusselle, K.R. Bracke, Effect of ACE1 polymorphism rs1799752 on protein levels of ACE2, the SARS-CoV-2 entry receptor, in alveolar lung epithelium, ERJ. Open. Res. 7 (2021) 00940–2020, https://doi.org/10.1183/23120410.00940-2020.

[27] S. Verma, M. Abbas, S. Verma, F.H. Khan, S.T. Raza, Z. Siddiqi, I. Ahmad, F. Mahdi, R. Poledne, P. Stachura, J. Pitha, A FTO variant and risk of acute coronary syndrome, Clin. Chim. Acta 411 (2010) 1069–1072, https://doi.org/10.1016/j.cca.2010.03.037.

[28] J.A. Hubacek, J. Pitha, I. Podrapska, J. Sochman, V. Adamkova, V. Longitudinal study in the Czech population: a growing burden of cardiovascular disease [ACE gene polymorphism and cardiovascular diseases]. Czech MONICA and Czech post-MONICA, Atherosclerosis 211 (2010) 676–681, https://doi.org/10.1016/j.atherosclerosis.2010.04.007.

[29] J.A. Hubacek, V. Stanek, M. Gebauerová, A. Púlipčíková, D. Douša, R. Poledne, M. Aschermann, H. Skalická, J. Matousková, A. Kruger, M. Penicka, H. Hrabáková, J. Veselka, P. Hájek, V. Lánská, V. Adámková, J. Pitha, A FTO variant and risk of acute coronary syndrome, Clin. Chim. Acta 411 (2010) 1069–1072, https://doi.org/10.1016/j.cca.2010.03.037.

[30] J.A. Hubacek, J. Pitha, I. Podrapska, J. Sochman, V. Adámková, V. Lánská, R. Poledne, Insertion/deletion polymorphism in the angiotensin-converting enzyme gene in myocardial infarction survivors, Med. Sci. Monit. 6 (2000) 503–506.

[31] S.A. Miller, D.D. Dykes, H.P. Polesky, A simple salting out procedure for DNA extraction from human nucleated cells, Nucleic Acid Res. 16 (1988) 1215, https://doi.org/10.1093/nar/16.3.1215.